Research Topics
| Kim N ChiSummaryAffiliation: British Columbia Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancerEmma K Beardsley
BC Cancer Agency, Vancouver, Canada
Curr Opin Support Palliat Care 2:161-6. 2008..The purpose of this article is to review recent developments in this area...- A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07aK N Chi
Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, Vancouver, BC, Canada
Ann Oncol 23:53-8. 2012..The purpose of this study was to determine the clinical activity of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel... - A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancerKim N Chi
British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada
Clin Cancer Res 14:833-9. 2008..The objective of this study was to determine a recommended phase II dose of OGX-011 in combination with docetaxel... - Castration-resistant prostate cancer: from new pathophysiology to new treatment targetsKim N Chi
BC Cancer Agency, Vancouver, British Columbia, Canada
Eur Urol 56:594-605. 2009..Castration-resistant prostate cancer (CRPC) refers to patients who no longer respond to surgical or medical castration. Standard treatment options are limited... - A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancerK N Chi
Department of Medical Oncology, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia
Ann Oncol 19:746-51. 2008..The purpose of this trial was to evaluate the antitumor activity of sorafenib, a multikinase inhibitor of cell proliferation and angiogenesis, in patients with castration-resistant prostate cancer... - Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancerKim N Chi
BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada
World J Urol 23:33-7. 2005..Randomized trials are required to determine if oblimersen can enhance the effectiveness of docetaxel in patients with HRPC... - A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancerKim N Chi
Vancouver Cancer Centre, BC Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada
J Natl Cancer Inst 97:1287-96. 2005..The primary objective of this clinical study was to determine a biologically effective dose of OGX-011 that would inhibit clusterin expression in human cancer... - A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancerKim N Chi
BC Cancer Agency, Vancouver, British Columbia, Canada
Invest New Drugs 23:311-5. 2005..Phase I trials of ONT-093 in normal human volunteers showed no dose-limiting toxicities at serum concentrations associated with biologic activity achieved with doses ranging from 300 to 500 mg... - Antisense approaches in prostate cancerKim N Chi
BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada
Expert Opin Biol Ther 4:927-36. 2004.... - Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
J Clin Oncol 28:4247-54. 2010..To determine the clinical activity of OGX-011, an antisense inhibitor of clusterin, in combination with docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer... - A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancerK N Chi
Vancouver Cancer Centre, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6
Clin Cancer Res 7:3920-7. 2001..In this dose escalation study, we evaluated the combination of Genasense and mitoxantrone, a standard chemotherapy for patients with HRPC... - Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancerKim N Chi
Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro Oncology Group, Vancouver, British Columbia, Canada
J Urol 180:565-70; discussion 570. 2008..We assessed pathological outcomes as well as the feasibility of combined docetaxel and androgen deprivation therapy in men with prostate cancer before undergoing prostatectomy... - Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyDaniel Y C Heng
FRCPC, Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada
J Clin Oncol 27:5794-9. 2009..There are no robust data on prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF) -targeted therapy... - Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British ColumbiaAbdulwahab J Al-Tourah
Vancouver Cancer Centre, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada
J Urol 174:2209-13, discussion 2213. 2005..2). CONCLUSIONS: For appropriately selected patients with CS I ECP NSGCT, primary surveillance results in fewer therapeutic interventions compared to RPLND without compromising the probability of cure... - Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancerBernhard J C Eigl
The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
Clin Cancer Res 11:4905-11. 2005..These findings provide preclinical proof-of-principle for ongoing clinical trials addressing the role and timing of systemic therapies in prostate cancer... - Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancersMartin Gleave
Division of Urology, University of British Columbia, The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia V5Z 3J5, Canada
Ann N Y Acad Sci 1058:1-15. 2005.... - Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgeryChristian Kollmannsberger
Division of Medical Oncology, British Columbia Cancer Agency Vancouver Cancer Centre, British Columbia, Canada
J Clin Oncol 28:537-42. 2010..The current study assesses the outcome for a modern, unselected patient population with disseminated testicular cancer with particular emphasis on those achieving a radiographic complete remission to combination chemotherapy... - A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancerDaniel Y C Heng
Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada
Cancer 115:776-83. 2009..This study aimed to determine overall survival and to confirm effectiveness in a population that includes poor prognosis patients... - Prednisone monotherapy in asymptomatic hormone refractory prostate cancerDaniel Y C Heng
Department of Medical Oncology, University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Can J Urol 13:3335-9. 2006..Prolonged time to progression and thus avoidance of more toxic chemotherapy is possible in some patients... - A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131K A Gelmon
British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC
Ann Oncol 15:1115-22. 2004..To assess its potential combined with a taxane, a phase I study of AMD473 and docetaxel in advanced cancer was initiated by the National Cancer Institute of Canada-Clinical Trials Group... - The standard of reporting of health-related quality of life in clinical cancer trialsC W Lee
Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
J Clin Epidemiol 53:451-8. 2000..Development and application of structured formats for presentation of HRQL may help to improve the standard of reporting of HRQL in the literature... - A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancerAnna Tinker
BC Cancer Agency, Vancouver, BC, Canada
Am J Clin Oncol 29:3-7. 2006..The preliminary objective response rate was high in this cohort of patients... - Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancerKim N Chi
The Prostate Centre at Vancouver General Hospital, 6th Floor, 2775 Laurel Street, Vancouver, V5Z 1M9, British Columbia, Canada
Expert Opin Investig Drugs 17:1955-62. 2008..Custirsen (OGX-011) is a 2'-methoxyethyl modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA; it is currently in clinical trials for patients with cancer... - A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancerJ Michels
Department of Medical Oncology, Vancouver Centre, British Columbia Cancer Agency, Vancouver, Canada
Ann Oncol 21:305-11. 2010.... - Novel targeted therapies for prostate cancerRobyn J Macfarlane
Division of Medical Oncology, BC Cancer Agency Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada
Urol Clin North Am 37:105-19, Table of Contents. 2010..There has also been interest generated by data from early-phase studies evaluating multitargeted tyrosine kinase inhibitors, agents effecting signal transduction pathways, and novel cytotoxics... - Asian race and impact on outcomes after radical radiotherapy for localized prostate cancerAda Man
Department of Radiation and Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, Canada V5Z 4E6
J Urol 170:901-4. 2003..Survival outcomes after radiotherapy are the same for the 2 populations... - Targeted therapy for metastatic renal cell carcinoma: current treatment and future directionsDaniel Y C Heng
BC Cancer Agency, 600 West 12 Avenue, Vancouver, British Columbia, V5Z 4E6, Canada
Ther Adv Med Oncol 2:39-49. 2010..Sequential and combination targeted therapies are currently under investigation in advanced disease as are adjuvant and neo-adjuvant approaches around nephrectomy... - Carboplatin and vinblastine for the treatment of metastatic transitional cell carcinoma of the urothelial tractHuda A Al-Karim
Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
Am J Clin Oncol 25:515-9. 2002..The combination of carboplatin and vinblastine given in this schedule is a feasible, well-tolerated, and active alternative for patients with metastatic TCC unfit for standard chemotherapy... - C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trialTomasz M Beer
Division of Hematology and Medical Oncology, Oregon Health and Sciences University, Portland, OR 97239, USA
Cancer 112:2377-83. 2008..The authors sought to determine whether specific blood proteins associated with inflammation predict for outcomes in men with metastatic androgen-independent prostate cancer (AIPC) who are initiating docetaxel-based chemotherapy... - Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerIan F Tannock
Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
N Engl J Med 351:1502-12. 2004..We compared such treatment with docetaxel plus prednisone in men with this disease... - Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT InvestigatorsTomasz M Beer
Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
J Clin Oncol 25:669-74. 2007..To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel... - High dose calcitriol may reduce thrombosis in cancer patientsTomasz M Beer
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
Br J Haematol 135:392-4. 2006..In vitro and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans... - Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancerGuru Sonpavde
Genitourinary Oncology Program, U S Oncology Research, Houston, Texas, USA
Cancer 110:2628-39. 2007..Recent and ongoing studies of neoadjuvant therapy followed by prostatectomy were reviewed... - Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxelTomasz M Beer
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
Cancer 112:326-30. 2008..In the current study, the authors examined retreatment with the same regimen after a treatment holiday... - A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancerEric Winquist
London Regional Cancer Centre, London, Ontario, Canada
Urol Oncol 23:143-9. 2005....